Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RGLS4326 · 1 trial · 1 indication
Changes in polycystin-1 (PC-1) and polycystin-2 (PC-2) protein levels in urinary exosomes from baseline to Day 44
| Arm | Type | Description |
|---|---|---|
| RGLS4326 1 mg/kg Q2W | EXPERIMENTAL | Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses |
| RGLS4326 0.3 mg/kg Q2W | EXPERIMENTAL | Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses |
| RGLS4326 0.1 or 0.5 mg/kg Q2W | EXPERIMENTAL | Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses |
| Name | Type | Description |
|---|---|---|
| RGLS4326 | DRUG | Solution for subcutaneous injection |
Inclusion Criteria: * Male or female ADPKD patients 18 to 70 years old * Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon prior MRI or CT Scan or MRI obtained during screening) * Estimated GFR at Screening between 30 to 90 mL/min/1.73 m\^2 calculated by the investigator using th...
RGLS4326 is an investigational small molecule being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by the growth of cysts in the kidneys. It is currently in clinical development for this condition.
RGLS4326 is being developed by Regulus Therapeutics Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RGLS. The company is conducting clinical research on this investigational drug for autosomal dominant polycystic kidney disease.
RGLS4326 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of RGLS4326 in patients with autosomal dominant polycystic kidney disease has been completed.
RGLS4326 has one completed clinical trial, NCT04536688, titled "A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease." This Phase 1 study enrolled 19 participants in the United States and included adults aged 18 years and older.
RGLS4326 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is identified by its code name RGLS4326 in clinical research.